For Immediate Release
Investor Contact: Media Contact:
|
INSPIRE ANNOUNCES DRY EYE PROGRAM UPDATE
DURHAM, NC -- January 4, 2007 -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today an update in its dry eye program.
Inspire provided additional information to the U.S. Food and Drug Administration (FDA) in November 2006 related toProlacria™ (the proposed U.S. trade name for diquafosol tetrasodium ophthalmic solution 2%). Inspire has been granted a meeting with the FDA to continue discussions regarding Inspire's dry eye clinical program and expects to provide an update on this program by the end of February 2007.
About Inspire
Forward-Looking Statements
The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Specifically, the anticipated timing of Inspire's update regarding the meeting granted with the FDA with respect to Inspire's dry eye clinical program is a forward-looking statement involving risks and uncertainties. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality ofElestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and co ntent of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. The FDA may request that the meeting it has granted regarding Inspire's dry eye clinical program be rescheduled. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.
# # #